Published 2022-08-01
“…Carole Bandiera,1– 3 Jérôme Pasquier,3 Isabella Locatelli,3 Anne Niquille,2,3 Grégoire Wuerzner,4 Jennifer Dotta-Celio,3 Anna Hachfeld,5 Gilles Wandeler,5 Anna Dorothea Wagner,6 Chantal Csajka,1,2,7 Anne Zanchi,4,8 Matthias Cavassini,9 Marie P Schneider1,2 1School of Pharmaceutical Sciences, University of Geneva, Geneva, Switzerland; 2Institute of Pharmaceutical Sciences of Western Switzerland, University of Geneva, University of Lausanne, Geneva, Switzerland; 3Center for Primary Care and Public Health (Unisanté), University of Lausanne, Lausanne, Switzerland; 4Service of Nephrology and Hypertension, Department of Medicine, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland; 5Department of Infectious Diseases, Bern University Hospital, University of Bern, Bern, Switzerland; 6Service of Oncology, Department of Medicine, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland; 7Center for Research and Innovation in Clinical Pharmaceutical Sciences, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland; 8Service of Endocrinology, Diabetes and Metabolism, Department of Medicine, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland; 9Service of Infectious Diseases, Department of Medicine, Lausanne University Hospital, University of Lausanne, Lausanne, SwitzerlandCorrespondence: Marie P Schneider, School of Pharmaceutical Sciences, University of Geneva, Rue Michel Servet 1, Geneva, 1211, Switzerland, Tel + 41 22 379 53 16, Email
Marie.Schneider@unige.chBackground: During the 2020 COVID-19 lockdown, patients included in the Interprofessional Medication Adherence Program (IMAP) in Switzerland continued to use electronic monitors (EMs) that registered daily drug-dose intake. …”
Get full text
Article